Provide NIAID with an immune T cell and antibody laboratory that can validated immune assays in support of phase II/III studies and product licensure and serve as a GLP resource for centralized immunogenicity testing across different NIAID sponsored vaccine projects, especially HIV vaccine work.Perform end point immunogenicity testing of candidate vaccines for both T-cell and humoral vaccine induced immune responses.Perform testing via validated analytical methodology for intracellular cytokine staining, ELISPOT, antibody ELISA, adenovirus serum neutralization assay, and any additional testing as requested by the study sponsors.Perform or facilitate performance of analysis to distinguish natural infections from vaccine induced responses and to characterize other immune responses among vaccine recipients
